Health & Environmental Research Online (HERO)


Print Feedback Export to File
2738902 
Journal Article 
Myelosuppression after methotrexate, mitoxantrone, and mitomycin C 
Jodrell, DI; Iveson, TJ; Smith, IE 
1987 
1 
The Lancet
ISSN: 0140-6736
EISSN: 1474-547X 
IPA/88/748166 
VOL 1 ISS May 23 1987 
REF 
English 
IPA COPYRIGHT: ASHP In a randomized trial, the myelotoxicity of mitoxantrone (mitozantrone), mitomycin (mitomycin C) and methotrexate (MMM) was compared with cyclophosphamide, methotrexate and fluorouracil (CMF) in 33 cancer patients. The results showed that MMM regimen has significant myelotoxicity, but no greater than that experienced with CMF. Dose reduction was required in 21% of patients. MMM appears otherwise to be relatively well tolerated with a preliminary response rate similar to that of CMF at around 50%.